Repligen Corporation to Present at 42nd Annual J.P. Morgan Healthcare Conference
19 Dezembro 2023 - 9:30AM
Repligen Corporation (NASDAQ:RGEN), a life sciences company focused
on bioprocessing technology leadership, today announced that it
will present at the 42nd Annual J.P. Morgan Healthcare conference
being held January 8-11 in San Francisco. Tony J. Hunt, Chief
Executive Officer, will present an overview of the company on
Tuesday, January 9, 2024, at 2:15 p.m. PST.
A live webcast of the presentation will be accessible through
Repligen’s Investor Relations website at www.repligen.com, and
will be available for replay for a limited period of time following
the event.
About Repligen
CorporationRepligen Corporation is a life sciences tools
and technology company that develops and markets highly innovative
bioprocessing solutions and systems. Our products enable
efficiencies in the process of manufacturing a wide range of
biological drugs, including: monoclonal antibodies; recombinant
proteins; cell and gene therapies; and vaccines. We are inspiring
advances in bioprocessing for the customers we serve around the
globe; primarily biopharmaceutical companies and contract
development and manufacturing organizations (CDMOs). Our corporate
headquarters are located in Waltham, Massachusetts, with additional
administrative and manufacturing operations worldwide. The majority
of our manufacturing sites are located within the U.S. (California,
Massachusetts, New Jersey and New York), and outside of the U.S. we
have sites in Estonia, France, Germany, Ireland, the Netherlands
and Sweden. For more information about the company, see our website
at www.repligen.com and follow us on LinkedIn.
Repligen Contact: Sondra S. NewmanGlobal Head
of Investor Relations(781) 419-1881investors@repligen.com
Repligen (NASDAQ:RGEN)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Repligen (NASDAQ:RGEN)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024